Microbot Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists
“As we continue to develop and perfect our novel technologies, it remains critical that we also attract extraordinary capabilities throughout the organization - management, Board of
Stephen B. Solomon, MD is Chief of the Interventional Radiology Service at Memorial Sloan Kettering, where he also holds the Enid A. Haupt Chair in Clinical Investigation. He is Director of Memorial Sloan Kettering’s Center for Image-Guided Interventionsand leads a research lab that works to improve image-guided cancer interventions. He treats kidney cancer, liver cancer, lung cancer and bone cancer, has an interest in treating tumors with thermal ablation and performs hepatic artery embolization. Dr. Solomonwas named a Castle Connolly: New York Magazine Top Doctor from 2012-2013 and 2015-2020. He received his undergraduate degree from Harvard, medical degree from Yale School of Medicine, and completed residencies at Yale-New Haven Hospitaland The John Hopkins Hospital. Gal Yaniv, MD, PhD is a founder and the Chief Medical Officer at Aidoc, contributing his expertise and knowledge to help in the continuing development of advanced, healthcare grade AI. He is currently the Director, Endovascular Neurosurgery unit at Sheba – Tel HaShomer hospital. A double graduate (M.D, PhD, cum laude on both) of the Technion – Israel Institute of Technology, Dr. Yanivcompleted his radiology residency at Sheba, Tel HaShomer hospital as well as diagnostic neuroradiology fellowship at Yale School of Medicineand endovascular neurosurgery fellowship at Mount Sinai Hospital. He has published numerous scientific publications focusing on basic science, radiology and public health, including a recent publication at the New England Journal of Medicine, and has presented in various scientific conferences worldwide. As a “Talpiot” alumni, he participates in the “Talpiot Medical Leadership Program” at Tel HaShomer Hospital. Dmitry J. Rabkin, MD, PhD, FSIR is a Vascular and Interventional Radiology Specialist, who is currently the Assistant Professor of Radiology at the Harvard Medical Schooland Assistant Chief of the Division of Interventional Radiologyat the Brigham and Women's Hospital. Previously, he was a Clinical Director and Chief of the Division of Interventional Radiologyat the Beth Israel Deaconess Medical Center, HMS, where he completed his residency in Diagnostic Radiology and a fellowship in Vascular and Interventional Radiology. He graduated from the First Moscow Medical School. Based on his achievements and contributions to the specialty, Dr. Rabkinhas been elected to Fellowship of the Society of Interventional Radiology. Dr. Rabkinhas been recognized as a Castle Connolly Top Doctorand Boston Magazine Top Doctorsince 2016 for his professional qualifications, reputation and clinical skills in the field of Interventional Radiology.
- Ajay K. Wakhloo, MD, PhD, FAHA is certified by the
American Board of Radiologyin Neuroradiology and Diagnostic Radiology, and he currently serves as Chief of Neurointerventional Radiology and Professor at TUFTS University School of Medicine. Prior to Tufts, he was a tenured Professor of Radiology, Neurology and Neurosurgery and the Director, Division NeuroImaging and Intervention (NII) in the Department of Radiology, University of Massachusetts Medical School. Earlier in his career, Dr. Wakhloo was a tenured Professor of Radiology, Neurological Surgery and Biomedical Engineering in the Department of Radiologyat the University of Miami, Miller School of Medicine. He received both his medical degree and Ph.D. from the University of Mainz, Germanyand completed his Internship and Residency in Internal Medicine at the University of Mainz. His training was continued at the University of Freiburg, Germanyin diagnostic and interventional Neuroradiology. He also completed fellowships in Neurosurgery at the University of Freiburgand Endovascular Neurosurgery at SUNY Buffalo, as well as Research Fellowships in Neurological Surgery at Barrow Neurological Instituteand in Neurosurgery at SUNY Buffalo. Ziv Neeman, MD is the Director of the Diagnostic Imaging Instituteand Nuclear Medicine at the Haemek Medical Center(Afula, Israel). He is affiliated with the Ruth & Bruce Rapport Faculty of Medicine (Technion, Israel) as Clinical Assistant Professor in the Diagnostic Radiology Department, where he trains medical students in the field of Diagnostic Imaging. He also serves as a guideline task force member for the European Society of Gastrointestinal Endoscopy. Dr. Neemancompleted fellowships at Beth Israel Deaconess(Abdominal Imaging) and Georgetown Universitymedical center (Interventional radiology). Prior clinical roles include Section Chief of Interventional Oncology in the Diagnostic Radiology Departmentat the National Institutes of Health (NIH) Clinical Center( Bethesda, MD), and Chairman of the Diagnostic Imaging Instituteat the Haemek Medical Center. He was a partner at Diagnostic Imaging Inc.( Philadelphia, PA), where he practiced vascular and interventional radiology, interventional oncology and diagnostic radiology. He has held academic appointments in the Diagnostic Radiology Departments at both the NIH, and the University of Maryland Medical Center( Baltimore, MD). Over the span of his career, Dr. Neemanhas published dozens of academic and clinical research articles in peer reviewed journals and serves as an ad hoc reviewer. He is a graduate of Ben Gurion Universityof the Negev Faculty of Health Sciences medical school, and completed an Abdominal Imaging fellowship at the Beth Israel Deaconess Medical Center(affiliated to the Harvard Medical School), Boston, MAand an Interventional and Vascular Radiology fellowship at the Georgetown University Medical Center, Washington, D.C, and is currently a member of the Israel Medical Association, the Israel Radiology Associationand the Radiological Society of North America(RSNA).
Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
Source: Microbot Medical